Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study

Liver Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study to Evaluate Different Criterion in Predicting Post-transplant Outcomes

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05036031

Acronym

TEA-ACLF

Enrollment

500

Registered

2021-09-05

Start date

2021-09-01

Completion date

2021-10-31

Last updated

2021-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute-On-Chronic Liver Failure, Liver Cirrhosis, Liver Transplant; Complications

Keywords

Acute-On-Chronic Liver Failure, EASL-CLIF criteria, APASL criteria

Brief summary

The definition and diagnostic criteria of acute-on chronic liver failure (ACLF) differed evidently between the East and the West due to the difference in the underlying etiology. Liver transplantation is the most effective treatment to reverse the progress of ACLF and improve the survival rate of patients. The purpose of this study is to explore the accuracy of the two diagnostic criteria of EASL-CLIF and APASL ACLF in assessing the survival rate of patients with liver cirrhosis after LT.

Detailed description

A retrospective collection and analysis of the preoperative conditions of patients with LT due to cirrhosis in a single center from January 2015 to June 2020 would be conducted, including epidemiological characteristics, etiology, clinical indicators, and short-term (28 days, 90 days) and long-term (1 year, 3 years) survival after LT.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* patients underwent liver transplantation for cirrhosis * The diagnosis of ACLF followed APASL and EASL-CLIF definition.

Exclusion criteria

* Patients with malignant tumor or underwent living donor liver transplantation (LDLT) were excluded.

Design outcomes

Primary

Measure	Time frame
3 years overall survival	Up to ~3 years

Contacts

Primary ContactHao Feng, MD., Ph.D.

surgeonfeng@live.com008615000901110

Outcome results